Designation: Professor
Department: Department of Medicine
University: Temple University of School of Medicine
Country: United States
Dan Liebermann has completed his first degree in Bachelor of Science from Tel Aviv University, Tel Aviv, Israel. He did his Ph.D. in the field of Molecular Genetics from Weizmann Institute of Sci., Rehovoth, Israel. He is currently working as a professor of Fels Institute for Cancer Research and Department of Medical Genetics in Molecular Biochemistry at Temple University School of Medicine. He received many awards in the research in the field of cancer genetics. He served on many international/national organizations and committees. He attended many international conferences. He published articles in many national and international journals.
His current research program is aimed at elucidating the role Gadd45 & MyD genes play in hematopoietic cell development, and growth arrest and apoptosis in general, as well as understanding how genetic lesions which impair Gadd45 & MyD gene expression or function,contribute to oncogenesis and inflammation, with an emphasis on blood cell malignancies and breast cancer.
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Send Information
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: support@boffinaccess.org
Copyright © 2020 Boffin Access Limited.